Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868005 | 1.00 | ALDH1A1 (0.45) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL4863360 | 0.98 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL6234929 | 0.87 | CTSL (0.46) | ALDH1A1DDB1CRBNCTSLCTSB | |
| SCHEMBL6235063 | 0.87 | CTSL (0.46) | ALDH1A1DDB1CRBNCTSLCTSB | |
| SCHEMBL6233007 | 0.85 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL6231440 | 0.85 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL4429190 | 0.84 | DDB1 (0.50) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL595870 | 0.83 | DDB1 (0.51) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL7228727 | 0.81 | DDB1 (0.52) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 | |
| SCHEMBL3555789 | 0.80 | DDB1 (0.51) | ALDH1A1DDB1CRBNMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | ALDH1A1 4302/4885DDB1 249/4885CRBN 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.